Alterity Therapeutics (PRNAD) Income from Continuing Operations (2009 - 2019)

Alterity Therapeutics (PRNAD) has reported Income from Continuing Operations for 5 consecutive years, with 7779671.49 the latest figure, recorded in Q4 2019.

• In Q4 2019, Income from Continuing Operations rose 3.44% year-over-year to 7779671.49; the TTM figure through Dec 2019 stood at 25990942.13 (down 144.94% YoY), while the FY2025 annual figure was 7779872.4, up 100.0% from the prior year.
• Income from Continuing Operations came in at 7779671.49 for Q4 2019 at Alterity Therapeutics, up from 8056698.76 in the prior quarter.
• The five-year high for Income from Continuing Operations was 4540192.17 in Q4 2017, with the low at 8056698.76 in Q4 2018.
• Average Income from Continuing Operations over 4 years is 6497735.53, with a median of 6697025.6 recorded in 2016.
• Across the five-year window, Income from Continuing Operations rose 19.13% in 2017 and plunged 77.45% in 2018, its largest moves.
• Year by year, Income from Continuing Operations stood at 5614379.72 in 2016, then grew by 19.13% to 4540192.17 in 2017, then slumped by 77.45% to 8056698.76 in 2018, then increased by 3.44% to 7779671.49 in 2019.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 7779671.49, 8056698.76, and 4540192.17 for Q4 2019, Q4 2018, and Q4 2017 respectively.